Boehringer Ingelheim’s survodutide phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing ...
In adults with insulin-treated type 2 diabetes, an automated insulin delivery system conferred lower HbA1c and improved time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results